- Home
- UROY vs LXEO Comparison
UROY vs LXEO Comparison
Compare UROY & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- LXEO
- Stock Information
- Founded
- UROY 2017
- LXEO 2017
- Country
- UROY Canada
- LXEO United States
- Employees
- UROY N/A
- LXEO N/A
- Industry
- UROY
- LXEO
- Sector
- UROY
- LXEO
- Exchange
- UROY Nasdaq
- LXEO Nasdaq
- Market Cap
- UROY 292.6M
- LXEO 252.4M
- IPO Year
- UROY N/A
- LXEO 2023
- Fundamental
- Price
- UROY $2.39
- LXEO $4.88
- Analyst Decision
- UROY Strong Buy
- LXEO Strong Buy
- Analyst Count
- UROY 2
- LXEO 5
- Target Price
- UROY $5.60
- LXEO $23.80
- AVG Volume (30 Days)
- UROY 2.0M
- LXEO 210.0K
- Earning Date
- UROY 03-14-2025
- LXEO 01-28-2025
- Dividend Yield
- UROY N/A
- LXEO N/A
- EPS Growth
- UROY 256.61
- LXEO N/A
- EPS
- UROY 0.03
- LXEO N/A
- Revenue
- UROY $27,478,292.00
- LXEO N/A
- Revenue This Year
- UROY N/A
- LXEO N/A
- Revenue Next Year
- UROY $34.24
- LXEO N/A
- P/E Ratio
- UROY $87.60
- LXEO N/A
- Revenue Growth
- UROY 31.26
- LXEO N/A
- 52 Week Low
- UROY $1.86
- LXEO $4.78
- 52 Week High
- UROY $3.76
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- UROY 54.77
- LXEO 29.67
- Support Level
- UROY $2.20
- LXEO $4.78
- Resistance Level
- UROY $2.45
- LXEO $7.66
- Average True Range (ATR)
- UROY 0.12
- LXEO 0.56
- MACD
- UROY 0.02
- LXEO -0.17
- Stochastic Oscillator
- UROY 82.28
- LXEO 3.47
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.